{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T23:15:24Z","timestamp":1769210124117,"version":"3.49.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,2,22]],"date-time":"2010-02-22T00:00:00Z","timestamp":1266796800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Previous health economic studies recommend either a dual screening strategy [tuberculin skin test (TST) followed by interferon-\u03b3-release assay (IGRA)] or a single one [IGRA only] for latent tuberculosis infection (LTBI), the former largely based on claims that it is more cost-effective. We sought to examine that conclusion through the use of a model that accounts for the additional costs of adverse drug reactions and directly compares two commercially available versions of the IGRA: the Quantiferon-TB-Gold-In-Tube (QFT-GIT) and T-SPOT.<jats:italic>TB<\/jats:italic>.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A LTBI screening model directed at screening contacts was used to perform a cost-effectiveness analysis, from a UK healthcare perspective, taking into account the risk of isoniazid-related hepatotoxicity and post-exposure TB (2 years post contact) using the TST, QFT-GIT and T-SPOT.<jats:italic>TB<\/jats:italic> IGRAs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Examining costs alone, the TST\/IGRA dual screening strategies (TST\/T-SPOT.<jats:italic>TB<\/jats:italic> and TST\/QFT-GIT; \u00a3162,387 and \u00a3157,048 per 1000 contacts, respectively) cost less than their single strategy counterparts (T-SPOT.<jats:italic>TB<\/jats:italic> and QFT-GIT; \u00a3203,983 and \u00a3202,921 per 1000 contacts) which have higher IGRA test costs and greater numbers of persons undergoing LTBI treatment. However, IGRA alone strategies direct healthcare interventions and costs more accurately to those that are truly infected.<\/jats:p>\n            <jats:p>Subsequently, less contacts need to be treated to prevent an active case of TB (T-SPOT.<jats:italic>TB<\/jats:italic> and QFT-GIT; 61.7 and 69.7 contacts) in IGRA alone strategies. IGRA single strategies also prevent more cases of post-exposure TB. However, this greater effectiveness does not outweigh the lower incremental costs associated with the dual strategies. Consequently, when these costs are combined with effectiveness, the IGRA dual strategies are more cost-effective than their single strategy counterparts. Comparing between the IGRAs, T-SPOT.<jats:italic>TB<\/jats:italic>-based strategies (single and dual; \u00a339,712 and \u00a337,206 per active TB case prevented, respectively) were more cost-effective than the QFT-GIT-based strategies (single and dual; \u00a342,051 and \u00a337,699 per active TB case prevented, respectively). Using the TST alone was the least cost-effective (\u00a347,840 per active TB case prevented). Cost effectiveness values were sensitive to changes in LTBI prevalence, IGRA test sensitivities\/specificities and IGRA test costs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>A dual strategy is more cost effective than a single strategy but this conclusion is sensitive to screening test assumptions and LTBI prevalence.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2466-10-7","type":"journal-article","created":{"date-parts":[[2010,2,23]],"date-time":"2010-02-23T07:15:19Z","timestamp":1266909319000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis"],"prefix":"10.1186","volume":"10","author":[{"given":"Anil","family":"Pooran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Booth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert F","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoff","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motasim","family":"Badri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim F","family":"Huggett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham","family":"Rook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alimuddin","family":"Zumla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keertan","family":"Dheda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,2,22]]},"reference":[{"issue":"3","key":"177_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/01.mcp.0000158726.13159.5e","volume":"11","author":"K Dheda","year":"2005","unstructured":"Dheda K, Udwadia ZF, Huggett JF, Johnson MA, Rook GA: Utility of the antigen-specific interferon-gamma assay for the management of tuberculosis. Curr Opin Pulm Med. 2005, 11 (3): 195-202. 10.1097\/01.mcp.0000158726.13159.5e.","journal-title":"Curr Opin Pulm Med"},{"issue":"5","key":"177_CR2","doi-asserted-by":"publisher","first-page":"340","DOI":"10.7326\/0003-4819-146-5-200703060-00006","volume":"146","author":"D Menzies","year":"2007","unstructured":"Menzies D, Pai M, Comstock G: Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Annals of internal medicine. 2007, 146 (5): 340-354.","journal-title":"Annals of internal medicine"},{"issue":"12","key":"177_CR3","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S1473-3099(04)01206-X","volume":"4","author":"M Pai","year":"2004","unstructured":"Pai M, Riley LW, Colford JM: Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis. 2004, 4 (12): 761-776. 10.1016\/S1473-3099(04)01206-X.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"177_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.7326\/0003-4819-149-3-200808050-00241","volume":"149","author":"M Pai","year":"2008","unstructured":"Pai M, Zwerling A, Menzies D: Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Annals of internal medicine. 2008, 149 (3): 177-184.","journal-title":"Annals of internal medicine"},{"issue":"11","key":"177_CR5","first-page":"1192","volume":"10","author":"M Farhat","year":"2006","unstructured":"Farhat M, Greenaway C, Pai M, Menzies D: False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria?. Int J Tuberc Lung Dis. 2006, 10 (11): 1192-1204.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6","key":"177_CR6","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1378\/chest.06-2471","volume":"131","author":"A Lalvani","year":"2007","unstructured":"Lalvani A: Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy. Chest. 2007, 131 (6): 1898-1906. 10.1378\/chest.06-2471.","journal-title":"Chest"},{"key":"177_CR7","volume-title":"Clinical diagnosis and management of tuberculosis, and measures for its prevention and control: Clinical Guideline 33","author":"National Institute for Health and Clinical Excellence","year":"2006","unstructured":"National Institute for Health and Clinical Excellence: Clinical diagnosis and management of tuberculosis, and measures for its prevention and control: Clinical Guideline 33. 2006, [http:\/\/guidance.nice.org.uk\/CG33\/costreport\/]"},{"issue":"RR-15","key":"177_CR8","first-page":"49","volume":"54","author":"GH Mazurek","year":"2005","unstructured":"Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A: Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep. 2005, 54 (RR-15): 49-55.","journal-title":"MMWR Recomm Rep"},{"issue":"5","key":"177_CR9","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1378\/chest.06-2728","volume":"131","author":"R Diel","year":"2007","unstructured":"Diel R, Nienhaus A, Loddenkemper R: Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in Germany. Chest. 2007, 131 (5): 1424-1434. 10.1378\/chest.06-2728.","journal-title":"Chest"},{"issue":"2","key":"177_CR10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1183\/09031936.00145906","volume":"30","author":"R Diel","year":"2007","unstructured":"Diel R, Wrighton-Smith P, Zellweger JP: Cost-effectiveness of interferon-gamma release assay testing for the treatment of latent tuberculosis. Eur Respir J. 2007, 30 (2): 321-332. 10.1183\/09031936.00145906.","journal-title":"Eur Respir J"},{"issue":"12","key":"177_CR11","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1016\/j.rmed.2009.07.008","volume":"103","author":"R Diel","year":"2009","unstructured":"Diel R, Schaberg T, Loddenkemper R, Welte T, Nienhaus A: Enhanced cost-benefit analysis of strategies for LTBI screening and INH chemoprevention in Germany. Respiratory medicine. 2009, 103 (12): 1838-1853. 10.1016\/j.rmed.2009.07.008.","journal-title":"Respiratory medicine"},{"issue":"1","key":"177_CR12","first-page":"16","volume":"11","author":"O Oxlade","year":"2007","unstructured":"Oxlade O, Schwartzman K, Menzies D: Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis. Int J Tuberc Lung Dis. 2007, 11 (1): 16-26.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"177_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1183\/09031936.06.00005906","volume":"28","author":"P Wrighton-Smith","year":"2006","unstructured":"Wrighton-Smith P, Zellweger JP: Direct costs of three models for the screening of latent tuberculosis infection. Eur Respir J. 2006, 28 (1): 45-50. 10.1183\/09031936.06.00005906.","journal-title":"Eur Respir J"},{"issue":"1","key":"177_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1183\/09031936.06.00011806","volume":"28","author":"R Diel","year":"2006","unstructured":"Diel R, Nienhaus A, Lange C, Schaberg T: Cost-optimisation of screening for latent tuberculosis in close contacts. Eur Respir J. 2006, 28 (1): 35-44. 10.1183\/09031936.06.00011806.","journal-title":"Eur Respir J"},{"issue":"2","key":"177_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1001\/archinternmed.2008.524","volume":"169","author":"MA de Perio","year":"2009","unstructured":"de Perio MA, Tsevat J, Roselle GA, Kralovic SM, Eckman MH: Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers. Archives of internal medicine. 2009, 169 (2): 179-187. 10.1001\/archinternmed.2008.524.","journal-title":"Archives of internal medicine"},{"issue":"12","key":"177_CR16","first-page":"1414","volume":"12","author":"F Marra","year":"2008","unstructured":"Marra F, Marra CA, Sadatsafavi M, Moran-Mendoza O, Cook V, Elwood RK, Morshed M, Brunham RC, Fitzgerald JM: Cost-effectiveness of a new interferon-based blood assay, QuantiFERON-TB Gold, in screening tuberculosis contacts. Int J Tuberc Lung Dis. 2008, 12 (12): 1414-1424.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6","key":"177_CR17","doi-asserted-by":"publisher","first-page":"808","DOI":"10.7326\/0003-4819-94-6-808","volume":"94","author":"WC Taylor","year":"1981","unstructured":"Taylor WC, Aronson MD, Delbanco TL: Should young adults with a positive tuberculin test take isoniazid?. Annals of internal medicine. 1981, 94 (6): 808-813.","journal-title":"Annals of internal medicine"},{"key":"177_CR18","unstructured":"Bank of England: Consumer Price Inflation Calculator, 1750 to 2008. [http:\/\/www.bankofengland.co.uk\/education\/inflation\/calculator\/index1.htm]"},{"key":"177_CR19","doi-asserted-by":"crossref","unstructured":"Control and Prevention of Tuberculosis in the United Kingdom: Code of practice 2000. Thorax. 2000, 887-901.","DOI":"10.1136\/thorax.55.11.887"},{"issue":"3 Pt 1","key":"177_CR20","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1164\/ajrccm.161.3.9902005","volume":"161","author":"K Schwartzman","year":"2000","unstructured":"Schwartzman K, Menzies D: Tuberculosis screening of immigrants to low-prevalence countries. A cost-effectiveness analysis. Am J Respir Crit Care Med. 2000, 161 (3 Pt 1): 780-789.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"177_CR21","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1183\/09031936.95.08081384","volume":"8","author":"NP Thompson","year":"1995","unstructured":"Thompson NP, Caplin ME, Hamilton MI, Gillespie SH, Clarke SW, Burroughs AK, McIntyre N: Anti-tuberculosis medication and the liver: dangers and recommendations in management. Eur Respir J. 1995, 8 (8): 1384-1388. 10.1183\/09031936.95.08081384.","journal-title":"Eur Respir J"},{"key":"177_CR22","volume-title":"Isoniazid Hepatotoxicity","author":"RA Weiseger","year":"2007","unstructured":"Weiseger RA: Isoniazid Hepatotoxicity. 2007, [http:\/\/www.emedicine.com\/med\/topic1193.htm]"},{"key":"177_CR23","unstructured":"Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ. 1982, 60 (4): 555-564."},{"issue":"1","key":"177_CR24","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1164\/ajrccm\/137.1.215","volume":"137","author":"J Tsevat","year":"1988","unstructured":"Tsevat J, Taylor WC, Wong JB, Pauker SG: Isoniazid for the tuberculin reactor: take it or leave it. Am Rev Respir Dis. 1988, 137 (1): 215-220.","journal-title":"Am Rev Respir Dis"},{"key":"177_CR25","unstructured":"Health Protection Agency: Tuberculosis in the UK: Annual report on tuberculosis surveillance in the UK 2009. [http:\/\/www.hpa.org.uk\/web\/HPAwebFile\/HPAweb_C\/1259152022594]"},{"issue":"2","key":"177_CR26","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1086\/593965","volume":"30","author":"R Sahni","year":"2009","unstructured":"Sahni R, Miranda C, Yen-Lieberman B, Tomford JW, Terpeluk P, Quartey P, Johnson LT, Gordon SM: Does the implementation of an interferon-gamma release assay in lieu of a tuberculin skin test increase acceptance of preventive therapy for latent tuberculosis among healthcare workers?. Infect Control Hosp Epidemiol. 2009, 30 (2): 197-199. 10.1086\/593965.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"1","key":"177_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1136\/thorax.57.1.45","volume":"57","author":"GH Bothamley","year":"2002","unstructured":"Bothamley GH, Rowan JP, Griffiths CJ, Beeks M, McDonald M, Beasley E, Bosch van den C, Feder G: Screening for tuberculosis: the port of arrival scheme compared with screening in general practice and the homeless. Thorax. 2002, 57 (1): 45-49. 10.1136\/thorax.57.1.45.","journal-title":"Thorax"},{"key":"177_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1471-2334-6-47","volume":"6","author":"PK Dewan","year":"2006","unstructured":"Dewan PK, Grinsdale J, Liska S, Wong E, Fallstad R, Kawamura LM: Feasibility, acceptability, and cost of tuberculosis testing by whole-blood interferon-gamma assay. BMC Infect Dis. 2006, 6: 47-10.1186\/1471-2334-6-47.","journal-title":"BMC Infect Dis"},{"key":"177_CR29","volume-title":"Health Protection Agency position statement on the use of Interferon Gamma Release Assay (IGRA) tests for Tuberculosis (TB): Interim HPA guidance","author":"HPA Tuberculosis Program Board","year":"2008","unstructured":"HPA Tuberculosis Program Board: Health Protection Agency position statement on the use of Interferon Gamma Release Assay (IGRA) tests for Tuberculosis (TB): Interim HPA guidance. 2008, [http:\/\/www.hpa.org.uk\/web\/HPAwebFile\/HPAweb_C\/1214808549127]"},{"issue":"9519","key":"177_CR30","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/S0140-6736(06)68579-6","volume":"367","author":"G Ferrara","year":"2006","unstructured":"Ferrara G, Losi M, D'Amico R, Roversi P, Piro R, Meacci M, Meccugni B, Dori IM, Andreani A, Bergamini BM, et al: Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet. 2006, 367 (9519): 1328-1334. 10.1016\/S0140-6736(06)68579-6.","journal-title":"Lancet"},{"issue":"1","key":"177_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1164\/rccm.200402-179OC","volume":"170","author":"T Mori","year":"2004","unstructured":"Mori T, Sakatani M, Yamagishi F, Takashima T, Kawabe Y, Nagao K, Shigeto E, Harada N, Mitarai S, Okada M, et al: Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med. 2004, 170 (1): 59-64. 10.1164\/rccm.200402-179OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"177_CR32","first-page":"491","volume":"12","author":"P Ravn","year":"2005","unstructured":"Ravn P, Munk ME, Andersen AB, Lundgren B, Lundgren JD, Nielsen LN, Kok-Jensen A, Andersen P, Weldingh K: Prospective evaluation of a whole-blood test using Mycobacterium tuberculosis-specific antigens ESAT-6 and CFP-10 for diagnosis of active tuberculosis. Clin Diagn Lab Immunol. 2005, 12 (4): 491-496.","journal-title":"Clin Diagn Lab Immunol"},{"issue":"8","key":"177_CR33","first-page":"939","volume":"10","author":"SJ Tsiouris","year":"2006","unstructured":"Tsiouris SJ, Austin J, Toro P, Coetzee D, Weyer K, Stein Z, El-Sadr WM: Results of a tuberculosis-specific IFN-gamma assay in children at high risk for tuberculosis infection. Int J Tuberc Lung Dis. 2006, 10 (8): 939-941.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"8","key":"177_CR34","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1164\/rccm.200510-1563OC","volume":"173","author":"TR Sterling","year":"2006","unstructured":"Sterling TR, Bethel J, Goldberg S, Weinfurter P, Yun L, Horsburgh CR: The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med. 2006, 173 (8): 927-931. 10.1164\/rccm.200510-1563OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"177_CR35","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1097\/01.aids.0000191923.08938.5b","volume":"19","author":"K Dheda","year":"2005","unstructured":"Dheda K, Lalvani A, Miller R, Scott G, Booth H, Johnson M, Zumla A, Rook G: Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count. AIDS. 2005, 19: 2038-2041. 10.1097\/01.aids.0000191923.08938.5b.","journal-title":"AIDS"},{"issue":"9452","key":"177_CR36","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1016\/S0140-6736(04)17592-2","volume":"364","author":"S Liebeschuetz","year":"2004","unstructured":"Liebeschuetz S, Bamber S, Ewer K, Deeks J, Pathan AA, Lalvani A: Diagnosis of tuberculosis in South African children with a T-cell-based assay: a prospective cohort study. Lancet. 2004, 364 (9452): 2196-2203. 10.1016\/S0140-6736(04)17592-2.","journal-title":"Lancet"},{"issue":"11","key":"177_CR37","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1136\/thorax.55.11.962","volume":"55","author":"VL White","year":"2000","unstructured":"White VL, Moore-Gillon J: Resource implications of patients with multidrug resistant tuberculosis. Thorax. 2000, 55 (11): 962-963. 10.1136\/thorax.55.11.962.","journal-title":"Thorax"},{"issue":"8","key":"177_CR38","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","volume":"174","author":"JJ Saukkonen","year":"2006","unstructured":"Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, et al: An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006, 174 (8): 935-952. 10.1164\/rccm.200510-1666ST.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9364","key":"177_CR39","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/S0140-6736(03)12950-9","volume":"361","author":"K Ewer","year":"2003","unstructured":"Ewer K, Deeks J, Alvarez L, Bryant G, Waller S, Andersen P, Monk P, Lalvani A: Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet. 2003, 361 (9364): 1168-1173. 10.1016\/S0140-6736(03)12950-9.","journal-title":"Lancet"},{"issue":"9","key":"177_CR40","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1164\/rccm.200505-748OC","volume":"172","author":"H Shams","year":"2005","unstructured":"Shams H, Weis SE, Klucar P, Lalvani A, Moonan PK, Pogoda JM, Ewer K, Barnes PF: Enzyme-linked immunospot and tuberculin skin testing to detect latent tuberculosis infection. Am J Respir Crit Care Med. 2005, 172 (9): 1161-1168. 10.1164\/rccm.200505-748OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"177_CR41","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1164\/ajrccm.163.4.2009100","volume":"163","author":"A Lalvani","year":"2001","unstructured":"Lalvani A, Pathan AA, McShane H, Wilkinson RJ, Latif M, Conlon CP, Pasvol G, Hill AV: Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Am J Respir Crit Care Med. 2001, 163 (4): 824-828.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"177_CR42","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10096-005-1377-8","volume":"24","author":"T Meier","year":"2005","unstructured":"Meier T, Eulenbruch HP, Wrighton-Smith P, Enders G, Regnath T: Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice. Eur J Clin Microbiol Infect Dis. 2005, 24 (8): 529-536. 10.1007\/s10096-005-1377-8.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"9","key":"177_CR43","doi-asserted-by":"publisher","first-page":"5217","DOI":"10.4049\/jimmunol.167.9.5217","volume":"167","author":"AA Pathan","year":"2001","unstructured":"Pathan AA, Wilkinson KA, Klenerman P, McShane H, Davidson RN, Pasvol G, Hill AV, Lalvani A: Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol. 2001, 167 (9): 5217-5225.","journal-title":"J Immunol"},{"issue":"11","key":"177_CR44","first-page":"1311","volume":"12","author":"D Goletti","year":"2005","unstructured":"Goletti D, Vincenti D, Carrara S, Butera O, Bizzoni F, Bernardini G, Amicosante M, Girardi E: Selected RD1 peptides for active tuberculosis diagnosis: comparison of a gamma interferon whole-blood enzyme-linked immunosorbent assay and an enzyme-linked immunospot assay. Clin Diagn Lab Immunol. 2005, 12 (11): 1311-1316.","journal-title":"Clin Diagn Lab Immunol"},{"issue":"6","key":"177_CR45","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1093\/clinids\/17.6.968","volume":"17","author":"RE Huebner","year":"1993","unstructured":"Huebner RE, Schein MF, Bass JB: The tuberculin skin test. Clin Infect Dis. 1993, 17 (6): 968-975.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"177_CR46","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1183\/09031936.06.00016906","volume":"28","author":"JY Lee","year":"2006","unstructured":"Lee JY, Choi HJ, Park IN, Hong SB, Oh YM, Lim CM, Lee SD, Koh Y, Kim WS, Kim DS, et al: Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J. 2006, 28 (1): 24-30. 10.1183\/09031936.06.00016906.","journal-title":"Eur Respir J"},{"issue":"12 Suppl 2","key":"177_CR47","first-page":"S127","volume":"4","author":"Z Taylor","year":"2000","unstructured":"Taylor Z: The cost-effectiveness of screening for latent tuberculosis infection. Int J Tuberc Lung Dis. 2000, 4 (12 Suppl 2): S127-133.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"177_CR48","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1164\/ajrccm.149.5.8173779","volume":"149","author":"JB Bass Jr","year":"1994","unstructured":"Bass JB, Farer LS, Hopewell PC, O'Brien R, Jacobs RF, Ruben F, Snider DE, Thornton G: Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. Am J Respir Crit Care Med. 1994, 149 (5): 1359-1374.","journal-title":"Am J Respir Crit Care Med"},{"key":"177_CR49","doi-asserted-by":"crossref","unstructured":"Smieja MJ, Marchetti CA, Cook DJ, Smaill FM: Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev. 2000, CD001363-2","DOI":"10.1002\/14651858.CD001363"},{"issue":"2","key":"177_CR50","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1378\/chest.99.2.465","volume":"99","author":"MA Steele","year":"1991","unstructured":"Steele MA, Burk RF, DesPrez RM: Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest. 1991, 99 (2): 465-471. 10.1378\/chest.99.2.465.","journal-title":"Chest"},{"issue":"5","key":"177_CR51","first-page":"560","volume":"159","author":"SR Salpeter","year":"1993","unstructured":"Salpeter SR: Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis. West J Med. 1993, 159 (5): 560-564.","journal-title":"West J Med"},{"issue":"12","key":"177_CR52","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1086\/502343","volume":"25","author":"SR Salpeter","year":"2004","unstructured":"Salpeter SR, Salpeter EE: Screening and treatment of latent tuberculosis among healthcare workers at low, moderate, and high risk for tuberculosis exposure: a cost-effectiveness analysis. Infect Control Hosp Epidemiol. 2004, 25 (12): 1056-1061. 10.1086\/502343.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"177_CR53","first-page":"28","volume":"26","author":"SH Ferebee","year":"1970","unstructured":"Ferebee SH: Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc. 1970, 26: 28-106.","journal-title":"Bibl Tuberc"},{"issue":"10","key":"177_CR54","first-page":"847","volume":"3","author":"GW Comstock","year":"1999","unstructured":"Comstock GW: How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?. Int J Tuberc Lung Dis. 1999, 3 (10): 847-850.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6","key":"177_CR55","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1183\/09031936.05.00074004","volume":"25","author":"K Dasgupta","year":"2005","unstructured":"Dasgupta K, Menzies D: Cost-effectiveness of tuberculosis control strategies among immigrants and refugees. Eur Respir J. 2005, 25 (6): 1107-1116. 10.1183\/09031936.05.00074004.","journal-title":"Eur Respir J"},{"key":"177_CR56","unstructured":"UK Department of Health: National tariff 2005-06. [http:\/\/www.dh.gov.uk\/en\/Publicationsandstatistics\/Publications\/PublicationsPolicyAndGuidance\/DH_4091529]"},{"key":"177_CR57","unstructured":"Curtis L: Unit costs of health and social care 2007. [http:\/\/www.pssru.ac.uk\/pdf\/uc\/uc2007\/uc2007.pdf]"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2466-10-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2466-10-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2466-10-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2466-10-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T04:31:49Z","timestamp":1630470709000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/1471-2466-10-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,22]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["177"],"URL":"https:\/\/doi.org\/10.1186\/1471-2466-10-7","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,22]]},"assertion":[{"value":"6 November 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"7"}}